U.S. Real Estate Stock News

NYSE:FUN
NYSE:FUNHospitality

Six Flags Leadership Shakeup Meets Strong Valuation And Momentum Signals

Six Flags Entertainment (NYSE:FUN) has announced several senior leadership changes, including a new Chief Marketing Officer from Carnival Cruise Line. The company has appointed a new Chief Legal and Compliance Officer joining from Dentons. An Interim Chief Financial Officer has stepped in following the resignation of the previous CFO. These appointments come as Six Flags Entertainment trades around $22.76, with recent moves in the stock that include a 21.2% return over the past week and...
NasdaqGS:MGEE
NasdaqGS:MGEEElectric Utilities

MGE Energy’s $250m Equity Raise And What It Means For Investors

MGE Energy (NasdaqGS:MGEE) has launched a $250 million equity offering via an underwritten public offering and forward sale agreements. The company plans to use the net proceeds for general corporate purposes, including potential investments and balance sheet needs. The offering structure combines immediate share issuance with future share delivery through forward sale counterparties. MGE Energy operates as a regulated utility, so access to capital markets is central to funding projects and...
NYSE:LBRT
NYSE:LBRTEnergy Services

Liberty Energy Expands Beyond Oilfield Services With $505m Bergen Agreements

Liberty Energy (NYSE:LBRT) has entered into $505 million multi-year supply agreements with Bergen Engines. The contracts cover power generation equipment for future data center and distributed power projects. These agreements mark an expansion of Liberty Energy's activity beyond its traditional oilfield services focus. Liberty Energy, trading at $31.68, has seen strong share price performance, with the stock up 67.8% year to date and 172.0% over the past year. The company has also delivered...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Is It Too Late To Consider Corvus Pharmaceuticals (CRVS) After A 335% One Year Surge?

If you are wondering whether Corvus Pharmaceuticals stock still offers value after a big run, the next sections break down what the current price might imply about expectations. The stock recently closed at US$14.59, with a 1 year return of 335.5% and a year to date return of 99.3%, alongside a 4.0% decline over the last 7 days and a 1.7% gain over the past 30 days. Recent news coverage has focused on Corvus Pharmaceuticals within the context of its sector and ongoing product development...
NYSE:CBL
NYSE:CBLRetail REITs

Is It Too Late To Look At CBL & Associates Properties (CBL) After A 92% Year?

Wondering if CBL & Associates Properties at around US$43.95 is still good value after its recent run, or if most of the easy gains are already behind it. The stock has had a strong stretch, with a 19.0% return year to date and 91.9% over the last year, although the past week showed a 2.4% decline after a 7.2% gain in the last 30 days. Recent coverage has focused on CBL & Associates Properties as a retail focused real estate investment trust, with investors paying attention to how it is...
NasdaqGS:TWFG
NasdaqGS:TWFGInsurance

Assessing TWFG (TWFG) Valuation After Mixed Recent Share Price Performance

What TWFG’s Recent Share Moves Signal for Investors TWFG (TWFG) has drawn investor attention after recent share price moves, with the stock showing mixed short term performance, modest gains over the past month, but a sharper decline over the past 3 months and year. See our latest analysis for TWFG. At a share price of $19.35, TWFG’s recent 1 day and 7 day share price returns have been positive, but the 90 day share price return and 1 year total shareholder return both point to fading...
NYSE:HP
NYSE:HPEnergy Services

Is Helmerich & Payne (HP) Still Attractively Priced After Its 110% One Year Surge?

If you are wondering whether Helmerich & Payne at around US$36.90 is still offering value after a strong run, this breakdown will help you see how the current price stacks up against several valuation checks. The stock has had a mixed short term, with an 8.6% decline over the last 7 days, a 2.8% gain over the past 30 days, and returns of 23.2% year to date and 110.2% over the last year. Recent coverage has focused on Helmerich & Payne in the context of ongoing interest in energy services...
NYSE:MSA
NYSE:MSACommercial Services

MSA Safety Buys Autronica To Broaden Detection Reach And Earnings Potential

MSA Safety (NYSE:MSA) has signed a definitive agreement to acquire Norway based Autronica Fire & Security. The deal values Autronica at about $550–$555 million. The acquisition adds depth in fire and gas detection for petrochemical, oil and gas, maritime, and wider industrial markets. For investors tracking NYSE:MSA, this move comes with the stock around $171.9 and a value score of 4, alongside a 10.5% return over the past year and 25.6% over three years. The company has also posted a 6.0%...
NYSE:VIRT
NYSE:VIRTCapital Markets

Virtu Financial Links Market Making To Zerohash Digital Asset Liquidity

Virtu Financial (NYSE:VIRT) has joined zerohash's liquidity ecosystem as a market-making partner. The company is providing liquidity across zerohash's central limit order book and request for quote systems. The move connects Virtu's market-making capabilities with a growing digital asset infrastructure provider. For you as an investor, this move ties a traditional electronic market maker directly into a digital asset venue. Virtu Financial focuses on market making and trade execution across...
NYSE:FG
NYSE:FGInsurance

Is F&G Annuities & Life (FG) Priced Fairly After Recent Share Price Rebound?

If you are wondering whether F&G Annuities & Life is attractively priced or just looks cheap on the surface, its recent share performance gives a few clues worth unpacking. The stock last closed at US$27.08, with a 10.1% gain over the past month but a 9.0% decline over the last year and a 9.9% decline year to date, which may leave you questioning whether sentiment or fundamentals are in the driving seat. Recent coverage of F&G Annuities & Life has focused on its position as a listed insurer...
NasdaqGS:DOX
NasdaqGS:DOXIT

Does Amdocs (DOX) Offer Opportunity After A 27.6% One-Year Share Price Decline

If you are wondering whether Amdocs stock is starting to look like value or a value trap, the current share price puts that question front and center. The stock closed at US$65.14 recently, with returns of 0.7% over 7 days, a 1.9% decline over 30 days, an 18.7% decline year to date and a 27.6% decline over the last year. This naturally raises questions about how the market is reassessing both growth potential and risk. Recent coverage has focused on how Amdocs fits into broader shifts in...
NYSE:AGRO
NYSE:AGROFood

Is Adecoagro (AGRO) Attractive After A 72% Rally And Recent Pullback?

Wondering if Adecoagro's recent share price puts it at a bargain or already reflects its strengths? This article breaks down what the current valuation is really telling you. The stock last closed at US$13.37, with a 72.3% return year to date and a 59.0% return over the past year. This is set against shorter term pullbacks of 5.1% over 7 days and 11.0% over 30 days that may signal shifting sentiment around risk and reward. Recent news around global food supply resilience, agricultural input...
NasdaqGS:MXL
NasdaqGS:MXLSemiconductor

Is It Too Late To Consider MaxLinear (MXL) After A 6x One-Year Share Price Jump?

If you are wondering whether MaxLinear's recent share price move has left the stock looking expensive or still potentially interesting, the valuation story is where your attention should be. The stock last closed at US$82.37, with returns of 16.4% over 7 days, 347.4% over 30 days, 345.0% year to date and a very large 1 year gain that is more than 6x. These moves sit against a backdrop of ongoing interest in semiconductor stocks, with investors watching closely for updates on demand for...
NasdaqCM:TNYA
NasdaqCM:TNYABiotechs

Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026

Why the upcoming TN-401 data matters for Tenaya Therapeutics stock Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting. This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline...
NYSE:AGBK
NYSE:AGBKBanks

AGI ESOP Shelf Registration Raises Questions On Dilution And Dividends

AGI (NYSE:AGBK) has filed a substantial Shelf Registration tied to an Employee Stock Ownership Plan for a large block of Class A common shares. The filing outlines a framework for issuing ESOP related shares over time, which can influence the company’s capital structure and employee ownership levels. AGI, trading at $7.39, has had mixed recent performance, with the stock up 4.2% over the past week and 9.5% over the past month, while showing a 31.3% decline year to date. The new ESOP related...
NasdaqGM:ZLAB
NasdaqGM:ZLABBiotechs

Zai Lab Weighs New Pipeline Data And KarXT Launch Against Revenue Pressures

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...
NasdaqGS:DGII
NasdaqGS:DGIICommunications

Digi International Reshapes IoT Model As ARR Jumps 50%

Digi International acquired Jolt Software and Particle Industries, reshaping its Internet of Things (IoT) offering. The company reports that these deals, combined with organic growth, have lifted annual recurring revenue (ARR) by 50%. Management highlights strong cash flow as a key support for integrating these acquisitions into the existing business. Digi International (NasdaqGS:DGII) is drawing fresh attention as it leans harder into IoT platforms and recurring software revenue. The stock...
NYSE:MAIN
NYSE:MAINCapital Markets

Main Street Capital (MAIN) One Off Gain Skews High Margins And Challenges Earnings Decline Narrative

Main Street Capital (MAIN) has wrapped up FY 2025 with fourth quarter revenue of US$145.5 million and basic EPS of US$1.46. This sets the tone for a year in which trailing twelve month revenue reached US$566.4 million and EPS was US$5.52. Over recent periods, the company has reported quarterly revenue ranging between US$137.0 million and US$145.5 million, while basic EPS has moved between US$1.31 and US$1.46. Trailing net income for the year was US$493.4 million, as investors weigh those...
NasdaqGM:ESPR
NasdaqGM:ESPRPharmaceuticals

Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives

Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how...
NasdaqGS:GILT
NasdaqGS:GILTCommunications

Is It Too Late To Consider Gilat Satellite Networks (NasdaqGS:GILT) After Its 189% One Year Run?

If you are wondering whether Gilat Satellite Networks at around US$18.84 is priced for opportunity or disappointment, the starting point is to understand what the current valuation is really implying. The stock has posted returns of 2.1% over the last 7 days and 2.2% over the last 30 days, with year to date returns of 40.5% and a 1 year return of 189.0%, alongside a 3 year return of 243.2% and a 5 year return of 119.8%. Recent news flow around Gilat Satellite Networks has focused on its...
NYSE:APTV
NYSE:APTVAuto Components

Does Aptiv (APTV) Offer Value After This Year’s 27% Share Price Decline?

Wondering if Aptiv's current share price reflects its true worth, or if the recent swings are masking a clearer story about value. Aptiv closed at US$57.11, with returns of a 5.2% decline over 7 days, a 1.9% decline over 30 days, a 27.2% decline year to date, but a 10.3% gain over the past year, which can leave the stock looking quite different depending on the time frame you focus on. Those mixed returns sit against a backdrop of ongoing attention on Aptiv as an auto components supplier, as...
NasdaqGS:GEOS
NasdaqGS:GEOSEnergy Services

Geospace Technologies (GEOS) Q1 Loss Of US$9.8 Million Challenges Profitability Optimism

Geospace Technologies (GEOS) opened Q1 2026 with revenue of US$25.6 million and a basic EPS loss of US$0.76, alongside a trailing twelve month basic EPS loss of US$2.17 on revenue of US$99.2 million. Over recent quarters the company has reported revenue between US$18.0 million and US$37.2 million, while EPS has ranged from a profit of US$0.66 per share in Q1 2025 to several loss-making quarters since. For investors, that mix of fluctuating topline and persistent losses keeps the attention on...
NYSE:JHG
NYSE:JHGCapital Markets

Janus Henderson Group (JHG) Earnings Double Challenging Bearish Margin And Quality Concerns

Janus Henderson Group (JHG) closed out FY 2025 with fourth quarter revenue of US$1.1 billion and basic EPS of US$2.64, capping a trailing twelve month net income of US$798.3 million on basic EPS of US$5.25. Over the past year, total revenue has moved from US$2.5 billion on trailing basic EPS of US$2.57 to US$3.1 billion on trailing basic EPS of US$5.25, alongside an improvement in net profit margin from 16.1% to 25.8%. This puts earnings quality front and center for investors assessing the...
NasdaqCM:ASRT
NasdaqCM:ASRTPharmaceuticals

Assertio Holdings (ASRT) Q4 Loss Of US$11.9 Million Reinforces Ongoing Bearish Earnings Narrative

Assertio Holdings (ASRT) closed out FY 2025 with Q4 revenue of US$13.5 million and basic EPS of a US$1.86 loss, alongside a trailing twelve month revenue base of US$118.7 million and basic EPS of a US$4.74 loss. Over the past year, quarterly revenue has moved between US$26.5 million and US$49.5 million, while quarterly basic EPS has ranged from a US$2.56 loss to US$1.78, leaving investors focused on how these shifts are feeding through to underlying margins. See our full analysis for Assertio...